

Please type a plus sign (+) inside this box →

PTO/SB/08A/B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<p>Substitute for form 1449A/B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	10/558,159
				Filing Date	November 22, 2005
				First Named Inventor	JAMIL, Haris
				Group Art Unit	
				Examiner Name	
Sheet	1	of	6	Attorney Docket Number	239615

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Filing Date, if appropriate MM-DD-YYYY
		Document Number	Kind Code			
	AA	US- 4,774,085		09-27-1988	Fidler	
	AB	US- 4,952,408		08-28-1990	Rahman	
	AC	US- 5,424,073		06-13-1995	Rahman et al.	
	AD	US- 5,648,090		07-15-1997	Rahman et al.	
	AE	US- 5,744,460		04-28-1998	Muller et al.	
	AF	US- 6,056,973		05-02-2000	Allen et al.	
	AG	US- 6,090,955		07-18-2000	Reszka et al.	
	AH	US- 6,126,965		10-03-2000	Kasid et al.	
	AI	US- 6,146,659		11-14-2000	Rahman	
	AJ	US- 6,333,314		12-25-2001	Kasid et al.	
	AK	US- 6,461,637		10-08-2002	Rahman	
	AL	US- 6,469,058		10-22-2002	Grove et al.	
	AM	US- 6,559,129		05-06-2003	Kasid et al.	
	AN	US- 2003/0035830	A1	02-20-2003	Rahman et al.	
	AO	US- 2003/0215489	A1	11-20-2003	Kasid et al.	
	AP	US- 2003/0215492	A1	11-20-2003	Ahmad et al.	
	AQ	US- 2003/0219476	A1	11-27-2003	Ahmad et al.	
	AR	US- 2003/0225023	A1	12-04-2003	Kasid et al.	
	AS	US- 2003/0228317	A1	12-11-2003	Gokhale et al.	
	AT	US- 2003/0229040	A1	12-11-2003	Kasid et al.	
	AU	US- 2004/0005603	A1	01-08-2004	Kasid et al.	
	AV	US- 2004/0082771	A1	04-29-2004	Kasid et al.	
	AW	US- 2004/0106571	A1	06-03-2004	Kasid et al.	
	AX	US- 2004/0115714	A1	06-17-2004	Kasid et al.	
	AY	US- 2004/0248218	A1	12-09-2004	Kasid et al.	

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)-(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)-(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Please type a plus sign (+) inside this box → Approved for use through 07/31/2006. CMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<p>Substitute for form 1449A/B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	10/558,159
				Filing Date	November 22, 2005
				First Named Inventor	JAMIL, Haris
				Group Art Unit	
Examiner Name					
Sheet	2	of	6	Attorney Docket Number	239615

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Filing Date, if appropriate MM-DD-YYYY
		Document Number	Kind Code			
AZ	US-	2005/0002918	A1	01-06-2005	Strauss et al.	
BA	US-	2005/0019387	A1	01-27-2005	Rahman et al.	
BB	US-	2005/0148528	A1	07-07-2005	Gately	
BC	US-	2005/0153297	A1	07-14-2005	Ahmad et al.	
BD	US-	2005/0181037	A1	08-18-2005	Ahmad et al.	
BE	US-	2005/0202074	A1	09-15-2005	Rahman	
BF	US-	2005/0238706	A1	10-27-2005	Ahmad et al.	
BG	US-	2005/0249795	A1	11-10-2005	Zhang et al.	
BH	US-	2005/0266068	A1	12-01-2005	Ahmad et al.	
BI	US-	2005/0277611	A1	12-15-2005	Ahmad et al.	
BJ	US-	09/354,109			Kasid et al.	07-15-1999
BK	US-	09/930,283			Kasid et al.	08-16-2001
BL	US-	10/056,210			Kasid et al.	01-28-2002
BM	US-	10/239,598			Rahman	10-25-2000
BN	US-	10/680,313			Kasid et al.	10-06-2003
BO	US-	10/786,866			Zhang et al.	02-24-2004
BP	US-	10/842,189			Strauss et al.	05-09-2004
BQ	US-	11/010,158			Kasid et al.	12-10-2004
BR	US-	11/061,044			Ahmad et al.	02-18-2005
BS	US-	11/105,970			Ahmad et al.	04-14-2005
BT	US-	11/106,406			Ahmad et al.	04-14-2005
BU	US-	11/177,194			Ahmad et al.	07-08-2005
BV	US-	11/196,123			Zhang et al.	08-03-2005
BW	US-	11/201,810			Bhamidipati et al.	08-11-2005
BX	US-	11/287,530			Jamil et al.	11-22-2005

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/558,159
				Filing Date	November 22, 2005
				First Named Inventor	JAMIL, Haris
				Group Art Unit	
Sheet	3	of	6	Examiner Name	
				Attorney Docket Number	239615

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Filing Date, if appropriate MM-DD-YYYY
		Document Number	Kind Code			
BY	US- 60/041,192				Kasid et al.	03-21-1997
BZ	US- 60/165,236				Puri et al.	11-11-1999
CA	US- 60/229,842				Puri et al.	08-31-2000
CB	US- 60/241,069				Rahman et al.	10-16-2000
CC	US- 60/247,306				Rahman et al.	11-09-2000
CD	US- 60/264,062				Kumar et al.	01-26-2001
CE	US- 60/281,779				Kasid et al.	04-06-2001
CF	US- 60/281,780				Kasid et al.	04-06-2001
CG	US- 60/281,785				Kasid	04-06-2001
CH	US- 60/281,796				Kasid et al.	04-06-2001
CI	US- 60/294,285				Rahman et al.	05-29-2001
CJ	US- 60/314,959				Rahman et al.	08-24-2001
CK	US- 60/332,477				Strauss et al.	11-09-2001
CL	US- 60/371,116				Kasid et al.	04-10-2002
CM	US- 60/371,126				Kasid et al.	04-10-2002
CN	US- 60/382,031				Gokhale et al.	05-22-2002
CO	US- 60/382,411				Gately	05-20-2002
CP	US- 60/383,340				Ahmad et al.	05-24-2002
CQ	US- 60/384,222				Ahmad et al.	05-29-2002
CR	US- 60/404,668				Rahman et al.	08-20-2002
CS	US- 60/405,378				Zhang et al.	08-23-2002
CT	US- 60/419,277				Ahmad et al.	10-16-2002
CU	US- 60/429,285				Ahmad et al.	11-26-2002
CV	US- 60/438,659				Ahmad et al.	01-07-2003
CW	US- 60/444,958				Zhang et al.	02-03-2003

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Please type a plus sign (+) inside this box → Approved for use through 07/31/2006. OMB 0651-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/558,159
				Filing Date	November 22, 2005
				First Named Inventor	JAMIL, Haris
				Group Art Unit	
Examiner Name					
Sheet	4	of	6	Attorney Docket Number	239615

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Filing Date, if appropriate MM-DD-YYYY
		Document Number	Kind Code			
	CX	US- 60/446,895			Bhamidipati et al.	02-11-2003
	CY	US- 60/457,898			Gately et al.	03-26-2003
	CZ	US- 60/467,331			Ahmad et al.	05-02-2003
	DA	US- 60/472,664			Jamil et al.	05-22-2003
	DB	US- 60/480,669			Jamil et al.	06-23-2003
	DC	US- 60/495,260			Jamil et al.	08-13-2003
	DD	US- 60/514,658			Ahmad et al.	10-27-2003
	DE	US- 60/535,042			Ahmad et al.	01-07-2004
	DF	US- 60/556,843			Ahmad et al.	03-27-2004
	DG	US- 60/557,232			Ahmad et al.	03-29-2004
	DH	US- 60/577,414			Hussey et al.	06-05-2004
	DI	US- 60/583,833			Ahmad et al.	06-29-2004

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided?
		Office	Number	Kind Code				
	DJ	DE	39 36 328	A	05-02-1991	Schering AG		
	DK	DE	101 31 796	A	01-16-2003	Beiersdorf AG		
	DL	WO	93/18751	A	09-30-1993	Georgetown University		
	DM	WO	98/43095	A	10-01-1998	Georgetown University		
	DN	WO	00/01366	A	01-13-2000	NeoPharm, Inc.		
	DO	WO	01/34130	A	05-17-2001	Boulikas		
	DP	WO	01/34116	A	05-17-2001	P.N. Gerolymatos S.A.		
	DQ	WO	01/70220	A	09-27-2001	NeoPharm, Inc.		
	DR	WO	01/95946	A	12-20-2001	Transgene S.A.		

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → Approved for use through 07/31/2006. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/558,159
				Filing Date	November 22, 2005
				First Named Inventor	JAMIL, Haris
				Group Art Unit	
Examiner Name					
Sheet	5	of	6	Attorney Docket Number	239615

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided?
		Office	Number	Kind Code				
DS	WO	02/32400	A	04-25-2002	NeoPharm, Inc.			
DT	WO	02/058622	A	08-01-2002	NeoPharm, Inc.			
DU	WO	02/059337	C2	08-01-2002	Georgetown Univ. School of Medicine			
DV	WO	02/081639	A	10-17-2002	Georgetown Univ.			
DW	WO	02/081640	A	10-17-2002	Georgetown Univ.			
DX	WO	02/081641	A	10-17-2002	Georgetown Univ.			
DY	WO	02/081642	A	10-17-2002	Georgetown Univ.			
DZ	WO	03/018018	A	03-06-2003	NeoPharm, Inc.			
EA	WO	03/030864	A	04-17-2003	NeoPharm, Inc.			
EB	WO	03/039600	A	05-15-2003	NeoPharm, Inc.			
EC	WO	03/070221	A	08-28-2003	Georgetown Univ.			
ED	WO	03/099213	A	12-04-2003	NeoPharm, Inc.			
EE	WO	03/099830	A	12-04-2003	NeoPharm, Inc.			
EF	WO	03/102011	A	12-11-2003	NeoPharm, Inc.			
EG	WO	2004/017940	A	03-04-2004	NeoPharm, Inc.			
EH	WO	2004/017944	A	03-04-2004	NeoPharm, Inc.			
EI	WO	2004/035523	A	04-29-2004	NeoPharm, Inc.			
EJ	WO	2004/039817	A	05-13-2004	NeoPharm, Inc.			
EK	WO	2004/062569	A	07-29-2004	NeoPharm, Inc.			
EL	WO	2004/069224	A	08-19-2004	NeoPharm, Inc.			
EM	WO	2004/071466	A	08-26-2004	NeoPharm, Inc.			
EN	WO	2004/087758	A	10-14-2004	NeoPharm, Inc.			
EO	WO	2005/000266	A	01-06-2005	NeoPharm, Inc.			

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Please type a plus sign (+) inside this box → Approved for use through 07/31/2006, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>					<b>Complete if Known</b>	
					Application Number	10/558,159
					Filing Date	November 22, 2005
					First Named Inventor	JAMIL, Haris
					Group Art Unit	
Sheet	6	of	6	Attorney Docket Number	239615	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided?
		Office	Number	Kind Code				
	EP	WO	2005/000318	A	01-06-2005	NeoPharm, Inc.		
	EQ	WO	2005/042028	A	05-12-2005	NeoPharm, Inc.		
	ER	WO	2005/067632	A	07-28-2005	NeoPharm, Inc.		

OTHER - NON PATENT LITERATURE DOCUMENTS					Translation Provided?
Examiner Initials <sup>1</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			
	ES	CAPONIGRO et al., "Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy," <i>Anti-Cancer Drugs</i> , 12 (6), 489-497 (July 2001).			
	ET	DAMON et al., "Advances in rational combination chemotherapy," <i>Cancer Invest.</i> , 4, 421-444 (1986).			
	EU	LEWIS et al., "Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed," <i>Cancer Chemother. Pharmacol.</i> , 50, 257-265 (2002).			
	EV	PARK, "Liposome-based drug delivery in breast cancer treatment," <i>Breast Cancer Res.</i> , 4 (3), 95-99 (2002).			
	EW	PATHAK et al., "Potentiation of the effect of paclitaxel and carboplatin by antioxidant mixture on human lung cancer H520 cells," <i>J. Am. Coll. Nutr.</i> , 21 (5), 416-421 (2002).			
	EX	RICCI et al., "Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens," <i>Cancer</i> , 95, 1444-1450 (2002).			
	EY	SOCINSKI et al., "Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated stage IIIB/IV nonsmall cell lung carcinoma," <i>Cancer</i> , 95, 1520-1527 (2002).			
	EZ	THIGPEN, "The role of gemcitabine-based doublets in the management of ovarian carcinoma," <i>Semin. Oncol.</i> , 29 (1 Suppl. 1), 11-16 (2002).			

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.